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Abstract  26 
The outcome of infection with Leishmania infantum in dogs is variable, which is 27 
thought to be due to the nature of the immune response mounted by the host. As a 28 
consequence, the clinical signs and severity of canine leishmaniosis vary between 29 
individual dogs.  Host immunogenetic factors might play an important role in 30 
determining the outcome of infection. The aim of this study was to examine 31 
polymorphisms in innate and adaptive immune response genes, to determine whether 32 
any of these were associated with susceptibility or resistance to L. infantum 33 
infection. Genomic DNA was obtained from two groups: pet dogs in endemic 34 
regions of Europe and a group of Beagles exposed to sand fly infection as part of a 35 
vaccine study. Genotyping was performed using a SNP (single nucleotide 36 
polymorphism) array for selected immune response genes.  The first part of the study 37 
compared 62 clinical cases with 101 clinically unaffected dogs that were 38 
seronegative for Leishmania antibodies.  One SNP in the CIITA gene demonstrated a 39 
significantly higher minor allele frequency in the case group, compared with the 40 
control group at the individual SNP level after permutation, but was not significant 41 
after correction for multiple testing.  The second part of the study examined 48 42 
Beagle dogs exposed to L. infantum over two transmission seasons.  Twenty-seven 43 
dogs with a resistant phenotype (no evidence of clinical disease, seronegative at the 44 
end of the study period, negative on lymph node culture and only transiently PCR 45 
positive in bone marrow) were compared with 21 dogs demonstrating a susceptible 46 
phenotype (clinical disease, seropositive, positive lymph node culture and 47 
consistently PCR positive in bone marrow).  Three SNPs in TLR3, two SNPs in 48 
PTPN22 and one SNP in TLR4 and IL1A were associated with the susceptible 49 
phenotype in the Beagle group at the individual SNP level after permutation 50 
analysis, but were not significant after correction for multiple testing.  Further 51 
validation of these SNPs is required in a larger cohort of dogs, ideally with extreme 52 
phenotypes to confirm an association with the outcome of L. infantum infection. 53 
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Abbreviations 57 
CIITA: class II major histocompatibility complex transactivator, C6: complement 58 
C6, C7: complement C7, CLEC16A: C-type lectin domain family 16 member A, 59 
DEXI: dexamethasone-induced protein, DLA: dog leukocyte antigen, EDTA: 60 
ethylenediaminetetraacetic acid, ELISA: enzyme linked immuno-absorbant assay, 61 
EU: ELISA units, GAPDH: glyceraldehyde 3-phosphate dehydrogenase, gDNA: 62 
genomic DNA, GSPL: glycosphingophospholipids, GWAS: genome wide 63 
association study, HWE: Hardy Weinberg equilibrium, IFAT: indirect 64 
immunofluorescence assay, IFN: interferon IgG: immunoglobulin G, IL: interleukin, 65 
IL1A: interleukin-1 alpha,IL2RA: interleukin-2 receptor alpha, IL7R: interleukin-7 66 
receptor,IL15RA: interleukin-15 receptor alpha, LIFR: leukemia inhibitor factor 67 
receptor alpha, LPS: lipopolysaccharide, MAF: minor allele frequency, MHC: major 68 
histocompatability complex, NO: nitric oxide, PTPN22: protein tyrosine phosphatase 69 
non-receptor type 22, qPCR: quantitative PCR, SD: standard deviation, SLC11A1: 70 
solute carrier family 11 (formally NRAMP), SOCS1: suppressor of cytokine 71 
signalling 1, SNP: single nucleotide polymorphism, TLR: toll-like receptor 72 
 73 
Introduction 74 
Canine leishmaniosis is caused by the protozoan parasite Leishmania infantum, which 75 
is also responsible for zoonotic visceral and cutaneous leishmaniosis in humans 76 
(Gramiccia and Gradoni, 2005).  L. infantum is endemic in the Mediterranean basin, 77 
Central and South America and parts of Africa and Asia (Palatnik-de-Sousa and Day, 78 
2011), with evidence of emerging disease elsewhere (Maia and Cardoso, 2015), as a 79 
result of increasing phlebotomine sand fly vector distribution and dogs travelling to 80 
and from endemic areas potentially spreading disease to Northern areas of Europe 81 
(Shaw et al., 2009).   82 
There is a spectrum of clinical leishmaniosis in dogs, varying from mild skin lesions 83 
and localised lymphadenomegaly to multi-organ involvement and renal failure 84 
(Koutinas et al., 1999).  Disease progression and severity of clinical signs, and/or 85 
clinicopathological abnormalities observed, vary between individual dogs, which 86 
suggests that some dogs might be more resistant to disease than others.  Diagnosis of 87 
canine leishmaniosis is based on the presence of clinical signs and clinicopathological 88 
abnormalities compatible with disease, alongside diagnostic methods of determining 89 
infection with L. infantum (Solano-Gallego et al., 2009). The most commonly used 90 
indirect diagnostic methods are serological tests, including the indirect 91 
immunofluorescence assay (IFAT) and enzyme linked immunoabsorbant assay 92 
(ELISA), which determine the presence of Leishmania antibodies in the serum 93 
(Paltrinieri et al., 2010).  High anti-Leishmania antibody reactivity has been associated 94 
with high parasite loads and clinical disease (Solano-Gallego et al., 2001).  Direct 95 
demonstration of the parasite by cytological examination of affected tissues 96 
(Paltrinieri et al., 2010) or detection of Leishmania DNA in the tissues, using PCR or 97 
quantitative PCR (qPCR), are also used (Cortes et al., 2004; Francino et al., 2006).  A 98 
definitive diagnosis of canine leishmaniosis can be difficult to achieve, although there 99 
is a high index of suspicion for individuals with clinical signs of overt leishmaniosis 100 
and a highly positive serology result (Paltrinieri et al., 2010).  However, when dogs 101 
present with a low clinical suspicion index, or where anti- Leishmania antibody 102 
reactivity is low, multiple diagnostic tests might be required to confirm the diagnosis 103 
(Solano-Gallego et al., 2009; Paltrinieri et al., 2010).   104 
A number of host and parasite factors seem to play a role in determining the outcome 105 
of infection. The host immune response might be particularly important in disease 106 
outcome, with CD4+ T helper type 1 (Th1) lymphocytes and their ability to induce 107 
macrophages to kill intracellular amastigotes via production of IFN-γ considered to be 108 
crucial in controlling infection (Pinelli et al., 1994). Although the immune response in 109 
dogs affected with leishmaniosis has been studied in some detail, knowledge gaps still 110 
remain in terms of the precise mechanisms involved in disease 111 
susceptibility/resistance. 112 
It has been suggested that host immunogenetic factors might determine whether the 113 
immune response is protective or not. A previous study examined dog leukocyte 114 
antigen (DLA) genes, which encode MHC Class II molecules and found an association 115 
between one particular DLA haplotype and increased anti-Leishmania IgG and 116 
presence of Leishmania DNA in the bone marrow (Quinnell et al., 2003).  Genome 117 
wide association studies (GWAS) have also been performed more recently, in which 118 
polymorphisms on chromosomes 1 and 4 were found to be significant and a potential 119 
locus on chromosome 4 that includes immune response genes (IL7R, LIFR, C6 and 120 
C7) (Quilez et al., 2012). Two further SNPs have been associated with leishmaniosis, 121 
one located on chromosome 2, proposed to be in linkage with a causal variant in the 122 
IL2RA or IL15RA gene and another on chromosome 1, which might be in linkage with 123 
a gene involved in Notch signalling (Utsunomiya et al., 2015).  A more recent GWAS 124 
identified SNPs on chromosome 20 to be associated with increased TNF-α 125 
concentration in Leishmania antigen stimulated lymphocytes, whilst SNPs on 126 
chromosome 17 were associated with increased IL-10 concentration (Cortes et al., 127 
2012). 128 
The aim of this study was to interrogate polymorphisms in candidate innate and 129 
adaptive immune response genes in dogs naturally infected with L. infantum to 130 
determine whether there are associations with clinical disease and/or infection status. 131 
Methods 132 
 133 
Canine population and study design 134 
 135 
The study dogs consisted of two populations that were analysed separately. The first 136 
study comprised of pet dogs from two Leishmania endemic regions of Europe 137 
consisting of clinical cases and controls. The second study comprised of Beagle dogs 138 
kept outdoors in an endemic region and thus exposed to sand flies and Leishmania 139 
infection for two years and regularly monitored (longitudinal study). 140 
 141 
In Study 1, blood samples were obtained from dogs that presented to first-opinion 142 
veterinary practices, one in Paphos, Cyprus and the other in Zaragoza, Spain. Dogs 143 
vaccinated with Canileish (Virbac) or with a history of immunosuppressive therapy 144 
were excluded. Clinical cases of leishmaniosis were identified based on clinical 145 
examination and confirmation testing by PCR and serology.  Samples from clinically 146 
healthy control dogs, breed and age matched where possible, resident in the same 147 
endemic regions were also recruited through these veterinary practices.  Signed 148 
informed consent was obtained from owners for permission to use any excess blood 149 
for clinical research after completion of diagnostic testing.  Approval was granted from 150 
the Clinical Research Ethics Review Board of the Royal Veterinary College (reference 151 
number URN 2014 1292; date of approval 03/09/2014) for use of the samples in 152 
research. 153 
In Study 2, residual genomic DNA samples were provided from Beagles enrolled in a 154 
natural infection model, where dogs were studied over a 2 year period.  Clinical and 155 
clinicopathological abnormalities were observed over the period of the study and 156 
diagnostic testing was performed every 3 months after an initial 6 month exposure 157 
period. Leishmania testing included Immunofluorescence Antibody Test (IFAT) and 158 
nested PCR on the bone marrow and lymph node parasite culture as previously 159 
described (Oliva et al., 2014).  The study was approved by the Veterinary Board of the 160 
Italian Ministry of Health following the European Directive 86/609/EEC, adopted by 161 
the Italian Government with the Law 116/1992.  Approval was granted from the 162 
Clinical Research Ethics Review Board of the Royal Veterinary College (approval 163 
number URN 2015 1329; date of approval 05/03/2015) for the use of these samples in 164 
research. 165 
 166 
Diagnostic procedures 167 
 168 
i. Culture technique 169 
 170 
Parasite isolation by culture was performed on lymph node aspirates from dogs in 171 
Study 2.  Briefly, lymph node aspirates were cultured in Evans’ modified Tobie’s 172 
medium at 22.5°C and were examined for promastigote growth after 1 month (Oliva 173 
et al., 2006). 174 
 175 
ii. Molecular analyses 176 
 177 
Real-time qPCR for L. infantum kinetoplast DNA was performed for Study 1 (Shaw 178 
et al., 2009). Genomic DNA (gDNA) was extracted from EDTA blood samples using 179 
the GenElute Blood Genomic DNA Kit (Sigma-Aldrich, Dorset, UK) according to the 180 
manufacturer’s instructions.  This was submitted to the Acarus laboratory (Molecular 181 
Diagnostic Unit, Langford Vets, Bristol) for qPCR testing.  Results were normalised 182 
against the median GAPDH reference value for the group. Dogs were categorised as 183 
qPCR negative for Leishmania kinetoplast DNA if a CT value could not be determined 184 
for the sample.  Samples were categorised as borderline positive if they had a CT value 185 
>35 and considered positive if the CT value ≤35. 186 
Nested PCR for L. infantum kinetoplast DNA was performed on gDNA extracted from 187 
bone marrow samples from dogs in Study 2 as previously described (Oliva et al., 188 
2006).  Bone marrow samples from Leishmania-free dogs were used as negative 189 
controls in each step of the procedure.  The amplification products were analysed on 190 
1.5% (w/v) agarose gels and visualized under UV light. Positive samples yielded a 191 
PCR product of 358 bp. 192 
 193 
iii. Serological techniques 194 
 195 
ELISA testing was performed on serum samples from Study 1 dogs to assess the 196 
presence of anti-Leishmania antibodies as previously described (Solano-Gallego et al., 197 
2014). Results were quantified as ELISA units (EU), relative to the calibrator 198 
(arbitrarily set at 100 EU). The positive cut-off value had previously been established 199 
at 35 EU (mean + 4 SD of values from 80 dogs from a non- endemic area). Positive 200 
sera were classified as borderline (35-≤37 EU), low (37-≤150 EU) medium (150-≤300 201 
EU) or high (>300 EU). 202 
The IFAT was performed on serum samples from Study 2 dogs.  Briefly, L. infantum 203 
parasites (MHOM/TN/1980/IPT-1) were fixed to microscope slides. Serial dilutions 204 
of serum were added to the slides and incubated for 30 min at 35-37°C.  Serum 205 
antibody reactivity to parasites was detected using a fluorescent secondary rabbit anti-206 
dog IgG antibody (Sigma-Aldrich).  The antibody titre represents the final dilution at 207 
which at least 50% of the parasites were visible by fluorescence.  Titres ≥ 1:160 were 208 
considered to be positive for infection (Oliva et al., 2014). 209 
 210 
Genotyping of candidate canine immune response genes and data analysis 211 
 212 
Sequenom MassARRAY genotyping was performed at the Centre for Integrated 213 
Genomic Medical Research, University of Manchester as previously described (Short 214 
et al., 2007).  Twenty-four candidate genes were selected, consisting of both innate 215 
and adaptive immune response genes across different chromosomes (Supplementary 216 
Table 1).  Sixty-five SNPs had been reported previously (Supplementary Table 2) and 217 
a further 47 SNPs had been identified by sequence-based typing for other genetic 218 
studies undertaken at the Royal Veterinary College (Supplementary Table 3). 219 
The data was analysed using PLINK whole genome data analysis toolset version 1.07 220 
(http://pngu.mgh.harvard.edu/~purcell/plink/) (Purcell et al., 2007). Results were 221 
filtered according to the following criteria for quality control purposes: SNPs with a 222 
minor allele frequency (MAF) below 5% and a call rate below 90% were excluded 223 
from the analysis. Individuals with more than 10% of the SNP information missing 224 
(low genotyping rate) were also excluded from the study.  Hardy Weinberg 225 
equilibrium (HWE) was assessed for each SNP.  Whilst HWE amongst the case 226 
population can be indicative of selection, deviation from HWE in the controls can be 227 
a result of poor genotyping of these SNPs and HWE was therefore assessed in the 228 
Study 1 control population. 229 
Information about the chromosomal location of each SNP included in the array was 230 
included in the map document provided with the analysis results.  This was based on 231 
the NCBI dog genome assembly, version 3.1 232 
(http://www.ncbi.nlm.nih.gov/genome/85). 233 
SNPs were tested for association using Chi square analysis or Fisher’s exact test.  234 
SNPs were considered as candidate for further investigation if the p value was below 235 
the significance cut-off p<0.05.  Corrected p values for multiple testing were obtained 236 
after 1000 permutations.  For each permutation the maximum statistic across all SNPs 237 
was recorded and from this distribution of maximum statistics, the statistic in the top 238 
5% is used to give the corrected p value. Linkage disequilibrium and haplotype 239 
assignment was performed in Haploview 4.2 (Barrett et al., 2005).  Haplotypes were 240 
tested for association using logistic regression in PLINK. 241 
 242 
Results 243 
 244 
Diagnostic testing and case definition 245 
 246 
The first study examined a heterogenous group of dogs that presented to first opinion 247 
practices in two geographically distinct regions where L. infantum is endemic. Sixty-248 
two cases of leishmaniosis were recruited (50 dogs from Cyprus and 12 dogs from 249 
Spain).  One hundred and one controls were recruited (90 dogs from Cyprus and 11 250 
dogs from Spain). The clinical signs observed in the cases were variable 251 
(Supplementary Figure 1).  The most common clinical abnormalities observed were 252 
lymphadenomegaly (enlargement of the peripheral lymph nodes), weight loss and skin 253 
lesions.  Qualitative assessment of clinicopathological abnormalities as assessed by 254 
veterinarians from endemic regions based on in-house biochemistry, complete blood 255 
count and urinalysis was available (Supplementary figure 2) and anaemia and 256 
hyperproteinaemia, hyperglobulinaemia and hypoalbuminaemia were the most 257 
commonly described abnormalities. 258 
Serological testing revealed that all leishmaniosis cases (n=62) were highly positive 259 
(>350 EU) using the ELISA. Fifty-five of the 62 dogs were qPCR positive for 260 
Leishmania kinetoplast DNA in the blood, 4 dogs were borderline positive and 3 dogs 261 
were qPCR negative (Figure 1).  The majority of dogs (85/101) in the control group 262 
were negative in both ELISA and qPCR tests. Two control dogs were borderline 263 
positive for Leishmania antibodies by ELISA but qPCR negative and serum was not 264 
available for testing in 4 dogs, but these were qPCR negative. Ten dogs were positive 265 
by qPCR (7 of which were borderline) but were all ELISA negative. 266 
In Study 2, clinical and diagnostic test information was provided for 48 Beagle dogs 267 
selected from a larger research study designed to investigate susceptibility to L. 268 
infantum infection over a two-year period.  Twenty-seven dogs were considered to 269 
have a resistant phenotype as they did not display any clinical or clinicopathological 270 
abnormalities for the duration of the study, were only transiently Leishmania DNA 271 
positive in the bone marrow, were negative on lymph node culture and IFAT negative 272 
at the end of the study period.  In contrast, 21 dogs were considered to have a 273 
susceptible phenotype as they demonstrated clinical and clinicopathological 274 
abnormalities compatible with leishmaniosis, first detected 6 to 20 months from 275 
commencement of the study, remained consistently Leishmania DNA positive in the 276 
bone marrow, were positive on lymph node culture and were IFAT positive at the end 277 
of the study period. 278 
 279 
SNP array analysis 280 
 281 
Seventy-three SNPs were included in the final analysis after exclusions for low MAF 282 
(<5%), call rate below 90% or lack of variability.  Four SNPs significantly deviated 283 
from HWE (P<0.00001) in the control population; TLR1 c.1665T>C, TLR1 284 
c.1776T>C, IL6 c.572A>G and IL10 c.-1330G>A.  285 
Linkage disequilibrium between SNPs was estimated using D’, a normalised 286 
measure of allele association and by r2, the correlation coefficient between 2 SNPs.  287 
Multiple SNPs appeared to be in linkage disequilibrium and haplotype blocks were 288 
assigned in Haploview based on D’ confidence intervals as described previously 289 
(Gabriel et al., 2002). 290 
 291 
Case-control association study: Study 1  292 
 293 
After initial analysis, 6 individuals were excluded due to a genotyping rate of less than 294 
90% (2 cases, 4 controls).  The genotyping rate in the remaining individuals was 295 
95.2%.  The final analysis was therefore performed on 60 clinical cases and 97 296 
controls. Two SNPs showed significantly higher MAFs in the case group compared 297 
with the control group; CIITA c.2595C>T (p=0.008) and IL6 c.572A>G (p=0.008) 298 
(Table 2).  The SNP IL6 c.572A>G was not in HWE and no dogs were found to be 299 
heterozygous at that position in our study population.  After permutation was 300 
performed, only one SNP was significant at the individual SNP level, CIITA 301 
c.2595C>T (p=0.036) and neither SNP was significant after the correction for multiple 302 
testing, implemented during permutation (p>0.05). 303 
There were no significant differences in genotype frequencies between case and 304 
control group for any of the SNPs and no evidence of a significant dominant or 305 
recessive penetrance model for any of the SNPs (significance level p<0.05).  The 306 
CIITA c.2595C>T SNP did not demonstrate a significant difference in genotypes 307 
between cases and controls (p=0.080).  A recessive model for this SNP appeared to 308 
be the best fit, but there was no significant difference in frequency of the TT 309 
genotype or in the combined frequency of CT and CC genotypes between cases and 310 
controls (p=0.053). 311 
 312 
Case-control association study: Study 2 313 
 314 
Three individuals were excluded from the genetic analysis, due to having a genotyping 315 
rate <90% (1 susceptible, 2 resistant phenotypes).  Four SNPs showed significantly 316 
different MAFs in the susceptible phenotype group compared with the resistant 317 
phenotype group (Table 2).  Two SNPs had significantly higher MAFs in the 318 
susceptible group; TLR3 c.369C>T (p=0.020) and TLR4 c.1795G>A (p=0.036).  In 319 
contrast, two SNPs had significantly higher MAFs in the resistant group; TLR3 320 
c.1380T>C (p=0.015) and TLR3 c.1104T>C (p=0.015).  After permutation, all four 321 
SNPs were still significant at the individual SNP level (p<0.01) and three more SNPs 322 
were significant comparing the two groups; PTPN22 c.88-39G>A (p=0.040), PTPN22 323 
c.915+87T>C (p=0.047) and IL1A c.-151A>C (p=0.048).  However, after correction 324 
for multiple testing implemented during permutation, there was no significant 325 
difference seen in any of these SNPs comparing the two groups (p>0.05).   326 
The SNPs in TLR3 and TLR4 that demonstrated significantly different allele 327 
frequencies were also significant when genotype frequencies were assessed between 328 
the two groups (Table 3); TLR3 c.369C>T (p=0.015), TLR3 c.1104T>C (p=0.011), 329 
TLR3 c.1380T>C (p=0.011) and TLR4 c.1795G>A (p=0.033).  Two SNPs in PTPN22 330 
also demonstrated significant differences in genotype frequency between groups; 331 
PTPN22 c.-515T>C (p=0.016) and PTPN22 c.88-39G>A (p=0.035).  After 332 
permutation all five SNPs were still significant at the individual SNP level (p<0.05).  333 
However, after the correction for multiple testing implemented during permutation 334 
there was no significant difference between groups for  any of these SNPs (p>0.05).   335 
The TLR3 SNPs, TLR3 c.1380T>C and TLR3 c.1104T>C were in linkage 336 
disequilibrium (D’=1) and formed a haplotype.  There was a significant difference in 337 
the frequency of the TLR3 CC haplotype in the resistant phenotype dogs compared 338 
with the susceptible phenotype dogs, with the CC haplotype showing decreased odds 339 
of disease (OR= 0.207, p=0.010) (Table 4).  Haplotypes were still significant at the 340 
individual haplotype level after permutation (p=0.005).  However, after correction 341 
for multiple testing implemented during permutation, there was no significant 342 
difference seen between groups (p=0.092). 343 
The two PTPN22 SNPs, PTPN22 c.88-39G>A and PTPN22 c.915+87T>C were also 344 
in linkage disequilibrium (D’=1) and formed a haplotype with one other SNP, 345 
PTPN22 c.-515T>C, which did not appear to be associated at the individual SNP 346 
level.  The TAT haplotype showed decreased odds of disease (OR= 0.231, p=0.033), 347 
whilst the CGT and CGC haplotypes were not significantly associated with disease 348 
(p>0.05).  The TAT haplotype was significant at the individual haplotype level after 349 
permutation was implemented (p=0.039) but not after correction for multiple testing 350 
(p=0.326). 351 
 352 
Discussion 353 
 354 
Polymorphisms in innate and adaptive immune response genes were examined in 355 
different dog populations exposed to L. infantum infection to determine whether any 356 
of these were associated with disease susceptibility. Although some SNPs showed a 357 
significant association with the disease phenotype, these did not reach statistical 358 
significance after correction for multiple testing. 359 
A case-control study, performed using samples from a heterogeneous population of 360 
client-owned dogs, revealed a SNP (c.2595C>T) in the CIITA gene to be associated 361 
with canine leishmaniosis.  CIITA is a key transcriptional activator of MHC Class II, 362 
with studies in CIITA knockout mice demonstrating significantly lower MHC Class II 363 
expression in lymphoid tissues compared with wild type mice (Itoh-Lindstrom et al., 364 
1999).  There is evidence of CIITA gene variation influencing susceptibility to other 365 
infectious diseases in humans, with promoter polymorphisms being associated with 366 
persistent infection with hepatitis B virus (Zhang et al., 2007). Furthermore, a recent 367 
GWAS identified CIITA as a susceptibility gene for leprosy, which, like L. infantum, 368 
is an intracellular pathogen (Liu et al., 2015).   369 
The CIITA c.2595C>T SNP could be in linkage disequilibrium with an as yet 370 
unidentified polymorphism in the CIITA gene or another gene located nearby on 371 
chromosome 6.  Other genes, on the same chromosome, which might contain causal 372 
variants include CLEC16A, encoding a membrane associated endosomal protein, 373 
DEXI, which encodes a protein of unknown function and SOCS1, a suppressor of 374 
cytokine signalling; all of which have been found to be associated with immune-375 
mediated disease in humans (Davison et al., 2012).  Future studies should interrogate 376 
multiple SNPs in this region, to understand which genes, if any, might be of 377 
importance in susceptibility to canine leishmaniosis. 378 
Three SNPs in TLR3 were found to be associated with the disease phenotype in Beagle 379 
dogs; two of which were in linkage disequilibrium and did not appear to have 380 
independent effects.  A significant association with disease was also observed for a 381 
SNP in TLR4.  Although TLR3 recognises double stranded RNA, and is thus important 382 
for recognition of viral pathogens, there is some evidence that TLR3 might also 383 
recognise Leishmania parasites. One study indicated that by inhibiting expression of 384 
TLR3 by RNA interference production of nitric oxide (NO) and TNF-α by 385 
macrophages infected in vitro with L. donovani promastigotes was reduced (Flandin 386 
et al., 2006).  Furthermore, a recent study revealed a positive correlation between TLR3 387 
expression and parasite density in the skin of dogs in early experimental infection with 388 
L. infantum (Hosein et al., 2015).   389 
Potential Leishmania ligands for TLR4 are glycosphingophospholipids (GSPL), 390 
which have been shown to induce a TLR4 mediated inflammatory response and 391 
parasite clearance of L.donovani in mice (Karmakar et al., 2012).  In mouse models, 392 
TLR4 is key to controlling the number of L.major parasites (Kropf et al., 2004a; 393 
2004b).  In dogs infected with L. infantum, the role of TLR4 is unclear; a recent study 394 
demonstrated TLR4 expression in the lymph node and spleen was reduced in infected 395 
dogs, compared with uninfected controls (Hosein et al., 2015). 396 
Two SNPs in the PTPN22 gene appeared to be associated with disease at the individual 397 
SNP level, and one other PTPN22 SNP was significant at the genotype level.  PTPN22 398 
is a susceptibility gene for immune-mediated diseases in humans (Criswell et al., 399 
2005) and with Type 1 diabetes and hypoadrenocorticism in the dog (Short et al., 2007; 400 
2013).  PTPN22 is believed to inhibit activation of T cells by dephosphorylation of 401 
signal transduction mediators (Stanford and Bottini, 2014), however, the role of 402 
PTPN22 has not been investigated with respect to leishmaniosis.   403 
The SNPs associated with disease susceptibility, and the genes in which they were 404 
located, were different between the two studies.  These differences could be due to the 405 
breed profiles and nature of the two studies.  Furthermore, in Study 1, the control group 406 
of dogs were mostly negative by both ELISA and qPCR testing. These dogs are 407 
assumed to have been exposed to L. infantum infected sand flies, since they lived in 408 
endemic regions, however exposure to sand flies was likely variable due to differences 409 
in owner lifestyle. Test sensitivity for Leishmania DNA is thought to be low in 410 
peripheral blood, when compared with other tissues (Maia and Campino, 2008) and it 411 
is therefore possible that these dogs were infected at a low level that could not be 412 
detected.  An ELISA for the detection of IgG antibodies against sand fly saliva 413 
antigens has been shown to correlate with the number of feeding events (Hostomska 414 
et al., 2008; Vlkova et al., 2011) and could have been used to confirm exposure to sand 415 
flies if not exposure to L. infantum.  A small number of dogs within the control group 416 
were positive by either ELISA or by qPCR, but did not display any clinical signs and 417 
were possibly more representative of resistant dogs provided they remained 418 
asymptomatic.  Disease progression for these infected but clinically healthy dogs is 419 
variable, with longitudinal studies suggesting that some dogs develop severe disease 420 
in the short to medium term whereas other dogs remain free from clinical signs for 421 
long periods or even indefinitely (Quinnell et al., 2001; Oliva et al., 2006). There are 422 
other limitations to this genetic study in terms of the sample size and potential 423 
population stratification, which were difficult to overcome in terms of the availability 424 
of suitable samples from dogs in endemic regions. Use of a larger number of control 425 
dogs might have increased the power and reduced stratification effects (Cardon and 426 
Bell, 2001).  The Beagle dogs were selected from a larger trial population and were 427 
considered to represent extreme phenotypes in terms of resistance and susceptibility 428 
to Leishmania infection.   429 
 430 
Conclusions 431 
Although the study was likely to be underpowered, as a result of small sample size, 432 
several genes of interest have been identified that could be involved in susceptibility 433 
to canine leishmaniosis.  Identification of immune response genes involved in disease 434 
susceptibility could inform breeding and disease prevention strategies in the future, as 435 
well as more targeted selection of dogs for vaccine challenge studies.  Furthermore, 436 
these susceptibility genes might represent good targets for manipulation (e.g. via use 437 
of specific adjuvants) in development of immunomodulatory therapies and vaccines. 438 
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  628 
Figure Legends 629 
Figure 1 630 
Leishmania diagnostic summary for Study 1 clinical cases and controls.  Clinical 631 
case (n=62) and control (n=101) dogs were tested for Leishmania antibodies by 632 
ELISA and Leishmania DNA in the peripheral blood was assessed by qPCR.  +/- = 633 
positive/negative result, Sero = ELISA result, qPCR = qPCR result.  Cases are 634 
indicated by black bars and controls are indicated by grey bars. 635 
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